HIF1A and hepatocellular carcinoma: In addition, previous studies demonstrate that the AURKA inhibitor alisertib could inhibit the growth of HCC and neuroblastoma in vivo via the AURKA-AKT axis [31,32], and PI3K/AKT activation directly influences HIF-1α-regulated glycolytic pathways and accelerates malignant progression [33,34].